Large-cap Health Care company United Therapeutics has moved 0.3% so far today on a volume of 941,550, compared to its average of 368,993. In contrast, the S&P 500 index moved -1.0%.
United Therapeutics trades -97.28% away from its average analyst target price of $8854.49 per share. The 10 analysts following the stock have set target prices ranging from $5023.82 to $11774.6, and on average have given United Therapeutics a rating of buy.
If you are considering an investment in UTHR, you'll want to know the following:
-
United Therapeutics's current price is 66.6% above its Graham number of $144.59, which implies that at its current valuation it does not offer a margin of safety
-
United Therapeutics has moved 5.0% over the last year, and the S&P 500 logged a change of 10.0%
-
Based on its trailing earnings per share of 14.72, United Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of 16.4 while the S&P 500 average is 15.97
-
UTHR has a forward P/E ratio of 0.4 based on its forward 12 month price to earnings (EPS) of $638.87 per share
-
The company has a price to earnings growth (PEG) ratio of 0.04 — a number near or below 1 signifying that United Therapeutics is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 2.2 compared to its sector average of 4.16
-
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
-
Based in Silver Spring, the company has 985 full time employees and a market cap of $11.28 Billion.